The abstract is read at the publisher; the summary is JClub's.
TGx-HDACi, an 81-gene biomarker in human TK6 cells, identifies trichostatin A, valproic acid, and entinostat as HDAC inhibitors and yields BMCs that match enzyme-activity potency for TSA and VPA.
- Why it matters: Quantitative chemical assessment needs transcriptomic readouts that agree with direct HDAC enzyme activity, but biomarker applicability across inhibitor selectivity classes is uncertain.
- What they did: Human TK6 cells were treated with TSA, VPA, and the class I-selective inhibitor entinostat; HDAC enzyme activity and TGx-HDACi transcriptomic responses were modeled to derive BMCs.
- The result: TSA and VPA showed overlapping confidence intervals between TGx-HDACi and HDAC activity BMCs, while entinostat produced higher TGx-HDACi BMCs, implying reduced quantitative concordance for class I-selective inhibition.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.